Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN.

N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.

PMID:
31042825
2.

Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival.

Chan S, Sridhar P, Kirchner R, Lock YJ, Herbert Z, Buonamici S, Smith P, Lieberman J, Petrocca F.

Mol Cancer Ther. 2017 Dec;16(12):2849-2861. doi: 10.1158/1535-7163.MCT-17-0461. Epub 2017 Sep 6.

3.

Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy.

Sridhar P, Petrocca F.

Cancers (Basel). 2017 Jul 18;9(7). pii: E92. doi: 10.3390/cancers9070092. Review.

4.

Regulation of microRNA expression by HMGA1 proteins.

De Martino I, Visone R, Fedele M, Petrocca F, Palmieri D, Hoyos JM, Forzati F, Croce CM, Fusco A.

Oncogene. 2016 Nov 3;35(44):5817-5818. doi: 10.1038/onc.2016.136. Epub 2016 Jul 11. No abstract available.

PMID:
27399337
5.

Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.

Witt AE, Lee CW, Lee TI, Azzam DJ, Wang B, Caslini C, Petrocca F, Grosso J, Jones M, Cohick EB, Gropper AB, Wahlestedt C, Richardson AL, Shiekhattar R, Young RA, Ince TA.

Oncogene. 2017 Mar 23;36(12):1707-1720. doi: 10.1038/onc.2016.337. Epub 2016 Oct 3.

6.

Specific microRNAs are downregulated in human thyroid anaplastic carcinomas.

Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, Liu CG, Petrocca F, Troncone G, Calin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, Fusco A.

Oncogene. 2016 Sep 29;35(39):5214. doi: 10.1038/onc.2016.139. Epub 2016 Jun 27. No abstract available.

PMID:
27345412
7.

Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells.

Gilboa-Geffen A, Hamar P, Le MT, Wheeler LA, Trifonova R, Petrocca F, Wittrup A, Lieberman J.

Mol Cancer Ther. 2015 Oct;14(10):2279-91. doi: 10.1158/1535-7163.MCT-15-0201-T. Epub 2015 Aug 11.

8.

miR-200 promotes the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes.

Perdigão-Henriques R, Petrocca F, Altschuler G, Thomas MP, Le MT, Tan SM, Hide W, Lieberman J.

Oncogene. 2016 Jan 14;35(2):158-72. doi: 10.1038/onc.2015.69. Epub 2015 Mar 23.

9.

A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells.

Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ, Kung AL, Hide W, Ince TA, Lieberman J.

Cancer Cell. 2013 Aug 12;24(2):182-96. doi: 10.1016/j.ccr.2013.07.008.

10.

Promise and challenge of RNA interference-based therapy for cancer.

Petrocca F, Lieberman J.

J Clin Oncol. 2011 Feb 20;29(6):747-54. doi: 10.1200/JCO.2009.27.6287. Epub 2010 Nov 15. Review.

PMID:
21079135
11.

miR-200 enhances mouse breast cancer cell colonization to form distant metastases.

Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J.

PLoS One. 2009 Sep 29;4(9):e7181. doi: 10.1371/journal.pone.0007181.

12.

Micromanipulating cancer: microRNA-based therapeutics?

Petrocca F, Lieberman J.

RNA Biol. 2009 Jul-Aug;6(3):335-40. Epub 2009 Jul 14. Review.

PMID:
19535911
13.

Micromanagers of immune cell fate and function.

Petrocca F, Lieberman J.

Adv Immunol. 2009;102:227-44. doi: 10.1016/S0065-2776(09)01204-8. Review.

PMID:
19477322
14.

Regulation of microRNA expression by HMGA1 proteins.

De Martino I, Visone R, Fedele M, Petrocca F, Palmieri D, Martinez Hoyos J, Forzati F, Croce CM, Fusco A.

Oncogene. 2009 Mar 19;28(11):1432-42. doi: 10.1038/onc.2008.495. Epub 2009 Jan 26. Erratum in: Oncogene. 2016 Nov 3;35(44):5817-5818.

PMID:
19169275
15.

Micro-RNAs in gastrointestinal and liver disease.

Visone R, Petrocca F, Croce CM.

Gastroenterology. 2008 Dec;135(6):1866-9. doi: 10.1053/j.gastro.2008.10.074. Epub 2008 Nov 14. Review. No abstract available.

PMID:
19013167
16.

RIG-ing an antitumor response.

Petrocca F, Lieberman J.

Nat Med. 2008 Nov;14(11):1152-3. doi: 10.1038/nm1108-1152. No abstract available.

PMID:
18989278
17.

Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling.

Petrocca F, Vecchione A, Croce CM.

Cancer Res. 2008 Oct 15;68(20):8191-4. doi: 10.1158/0008-5472.CAN-08-1768. Review.

18.

Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer.

Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM.

Cancer Res. 2008 Aug 1;68(15):6162-70. doi: 10.1158/0008-5472.CAN-08-0144.

19.

E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer.

Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, Cavazzini L, Volinia S, Alder H, Ruco LP, Baldassarre G, Croce CM, Vecchione A.

Cancer Cell. 2008 Mar;13(3):272-86. doi: 10.1016/j.ccr.2008.02.013.

20.

MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle.

Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM, Fusco A.

Endocr Relat Cancer. 2007 Sep;14(3):791-8.

PMID:
17914108
21.

MicroRNA signatures in human ovarian cancer.

Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Ménard S, Croce CM.

Cancer Res. 2007 Sep 15;67(18):8699-707.

22.

Specific microRNAs are downregulated in human thyroid anaplastic carcinomas.

Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, Liu CG, Petrocca F, Troncone G, Calin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, Fusco A.

Oncogene. 2007 Nov 29;26(54):7590-5. Epub 2007 Jun 11. Erratum in: Oncogene. 2016 Sep 29;35(39):5214.

PMID:
17563749
23.

MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.

Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM.

JAMA. 2007 May 2;297(17):1901-8.

PMID:
17473300
24.

Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development.

Vecchione A, Baldassarre G, Ishii H, Nicoloso MS, Belletti B, Petrocca F, Zanesi N, Fong LY, Battista S, Guarnieri D, Baffa R, Alder H, Farber JL, Donovan PJ, Croce CM.

Cancer Cell. 2007 Mar;11(3):275-89.

25.

Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer.

Petrocca F, Iliopoulos D, Qin HR, Nicoloso MS, Yendamuri S, Wojcik SE, Shimizu M, Di Leva G, Vecchione A, Trapasso F, Godwin AK, Negrini M, Calin GA, Croce CM.

Cancer Res. 2006 Nov 1;66(21):10287-91.

26.

A microRNA expression signature of human solid tumors defines cancer gene targets.

Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM.

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61. Epub 2006 Feb 3.

Supplemental Content

Loading ...
Support Center